ONCOMED PHARMACEUTICALS
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cellsâ€. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
ONCOMED PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2004-08-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.oncomed.com
Total Employee:
51+
Status:
Active
Contact:
650-995-8200
Email Addresses:
[email protected]
Total Funding:
210.15 M USD
Technology used in webpage:
SPF LetsEncrypt Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Amazon Route 53 DigiCert SSL Pound Sterling Amazon SSL GoDaddy
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Pharmagap Inc.
Pharmagap is a company that develops therapeutic drugs for the treatment of cancer.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Vencerx Therapeutic
Vencerx Therapeutics is a biotechnology company developing targeted therapeutics for the autism spectrum
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Morgenthaler Ventures
Morgenthaler Ventures investment in Series B - OncoMed Pharmaceuticals
Phase4 Ventures
Phase4 Ventures investment in Series B - OncoMed Pharmaceuticals
The Vertical Group
The Vertical Group investment in Series B - OncoMed Pharmaceuticals
U.S. Venture Partners
U.S. Venture Partners investment in Series B - OncoMed Pharmaceuticals
Delphi Ventures
Delphi Ventures investment in Series B - OncoMed Pharmaceuticals
Bay Partners
Bay Partners investment in Series B - OncoMed Pharmaceuticals
DeNovo Ventures
DeNovo Ventures investment in Series B - OncoMed Pharmaceuticals
Adams Street Partners
Adams Street Partners investment in Series B - OncoMed Pharmaceuticals
Latterell Venture Partners
Latterell Venture Partners investment in Series B - OncoMed Pharmaceuticals
Latterell Venture Partners
Latterell Venture Partners investment in Series A - OncoMed Pharmaceuticals
Official Site Inspections
http://www.oncomed.com
- Host name: 207.232.148.132.host.secureserver.net
- IP address: 132.148.232.207
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "OncoMed Pharmaceuticals"
OncoMed Pharmaceuticals - Crunchbase Company …
OncoMed Pharmaceuticals is a biotechnology company developing novel therapeutics for the treatment of cancer. View contacts for OncoMed Pharmaceuticals to access new leads and connect with decision-makers.See details»
oncomed - where courage meets knowledge
Sep 8, 2020 We are oncomed – a Contract Development and Manufacturing Organization (CDMO) specialized in aseptic processing of oncology injectables in clinical and commercial …See details»
OncoMed - Wikipedia
In 2013, OncoMed's chief executive officer (CEO) was Paul Hastings, who took the post in 2006. As of 2007 , the company's head of R&D was John Lewicki, and the director of operations was Chuck Alaimo. While serving as OncoMed's CEO, Hastings was also a member of the board of directors for the California Healthcare Institute and the Bay Area Biosciences Association, as well as chairing the board of the Biotechnology Industry Organization. See details»
about us - oncomed
Oct 15, 2020 about us meet oncomed.who are we? future development statement Despite being established in 2010, we build on the decades long chemical and pharmaceutical industry …See details»
About Us - OncoMed
OncoMed Consulting, based in Montreal, Canada, is exclusively focussed on providing insights and solutions in the commercial oncology segment. We collaborate with executive leadership, …See details»
OncoMed Pharmaceuticals - Contacts, Employees, Board …
Organization. OncoMed Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. …See details»
oncomed
We are oncomed – a Contract Development and Manufacturing Organization (CDMO) specialized in aseptic processing of oncology injectables in clinical and commercial scales. We deliver …See details»
OncoMed Pharmaceuticals - Craft
OncoMed is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutic candidates directed to fundamental biologic pathways and targets thought to drive …See details»
oncomed - Crunchbase Company Profile & Funding
Organization. oncomed . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. oncomed manufactures cytostatic injections for the …See details»
OncoMed | Contact Us
Get in touch with OncoMed To better understand the insight and solutions we can provide to address any commercial oncology challenge you are confronting, please do not hesitate to …See details»
OncoMed Pharmaceuticals - PitchBook
OncoMed Pharmaceuticals General Information Description. OncoMed Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel …See details»
our story - oncomed
On August 20, 2010, company called oncomed manufacturing a. s. signed a purchase contract and on September 1, 2010, ONCOMED had its first ten employees. Since 2010, we have been …See details»
OncoMed Pharmaceuticals - Funding, Financials, Valuation
OncoMed Pharmaceuticals is registered under the ticker NASDAQ:OMED . Their stock opened with $17.00 in its Jul 18, 2013 IPO. Stock Symbol NASDAQ:OMED ; Valuation at IPO $770M; …See details»
Oncomed is on its way to becoming the top CDMO
Oct 23, 2019 This week, SpeakPharma speaks to Aleš Šima, Head of Business Development Department at oncomed manufacturing as a subsidiary of the German pharmaceutical …See details»
Mereo BioPharma, OncoMed agree to merge
OncoMed’s president and CEO Dr John Lewicki said: “We believe this is a value-enhancing transaction for both companies, forming an organization with a much expanded pipeline of …See details»
OncoMed | Sample Mandates
Many strategic planning experts, including OncoMed, advocate the benefits of an "outsider looking in" as it may bring fresh perspective to the planning process while also challenging the …See details»
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce …
Jun 17, 2010 OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of …See details»
UPDATE: OncoMed Pharmaceuticals Initiates Second Phase 1b …
Feb 18, 2014 OncoMed Pharmaceuticals (Nasdaq: OMED ), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, …See details»
OncoMed Pharmaceuticals Commences Third Phase 1b Clinical …
Feb 20, 2014 OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells. OncoMed has five anti-cancer …See details»